Results 231 to 240 of about 144,143 (306)

Cutaneous-to-Bronchial Rosai-Dorfman Disease without Lymphadenopathy: A Rare Case Report and Literature Review. [PDF]

open access: yesClin Cosmet Investig Dermatol
Bogomolets O   +4 more
europepmc   +1 more source

Therapeutic targeting of bleomycin‐induced pulmonary fibrosis by human bone marrow mesenchymal stem cell‐derived extracellular vesicles and/or pirfenidone: Impact of sex in mature adult mice

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited therapeutic options. This study compared the therapeutic effects of bone marrow mesenchymal stem cell‐derived extracellular vesicles (BM‐MSC‐EVs) with an IPF treatment, pirfenidone (PFD), in mature adult mice with established pulmonary ...
Jennie S. Charoenphannathon   +4 more
wiley   +1 more source

Pathophysiological and Molecular Features of DXd ADC‐Related Interstitial Pneumonitis in Cynomolgus Monkeys

open access: yesCancer Science, EarlyView.
An interstitial lung disease model for DXd antibody‐drug conjugates was established in cynomolgus monkeys by weekly dosing of a non‐targeting DXd ADC. Integrated analysis of bronchoalveolar lavage fluid–derived extracellular vesicle proteomics and lung single‐cell RNA sequencing reveals cell‐type‐resolved molecular features of DXd ADC‐related lung ...
Kazuyoshi Kumagai   +5 more
wiley   +1 more source

Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB–IIIA Non‐Small‐Cell Lung Cancer: Phase 2 neoSCORE Trial

open access: yesCancer Science, EarlyView.
Kaplan–Meier survival curves comparing two‐cycle versus three‐cycle neoadjuvant sintilimab plus chemotherapy. (A) Disease‐free survival (DFS). (B) Overall survival (OS). CI, confidence interval; HR, hazard ratio; NR, not reached. ABSTRACT The optimal number of neoadjuvant chemoimmunotherapy cycles for resectable non‐small cell lung cancer (NSCLC ...
Miner Shao   +13 more
wiley   +1 more source

Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer

open access: yesCancer Science, EarlyView.
The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto   +9 more
wiley   +1 more source

The human lung microbiome progressively diminishes in the distal alveolar regions. [PDF]

open access: yesNPJ Biofilms Microbiomes
Potratz P   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy